JG
ABUS icon

Jefferies Group’s Arbutus Biopharma ABUS Stock Holding History

Jefferies Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-14,100
Closed -$47K – 1622
2021
Q1 		$47K Buy
+14,100
New +$54.4K ﹤0.01% 1514
2019
Q2 		– Sell
-10,187
Closed -$36K – 2463
2019
Q1 		$36K Buy
+10,187
New +$39.1K ﹤0.01% 2219
2017
Q1 		– Sell
-10,300
Closed -$25K – 2275
2016
Q4 		$25K Sell
10,300
-900
-8% -$2.62K ﹤0.01% 2122
2016
Q3 		$39K Hold
11,200
– – ﹤0.01% 2108
2016
Q2 		$39K Buy
+11,200
New +$47.4K ﹤0.01% 2006

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jefferies Group's ABUS Position: Q2 2021 in Review

Jefferies Group sold out of Arbutus Biopharma (ABUS) in Q2 2021, closing a stake of 14,100 shares — an estimated $47K sold.

Jefferies Group first reported a position in ABUS in Q2 2016 and held it in 5 quarters. The position peaked at $47K in Q1 2021. 91 funds tracked by Wall St. Rank hold ABUS as of Q2 2021.

  • Jefferies Group reported no remaining Arbutus Biopharma position as of Q2 2021 after selling out during the quarter.
  • Jefferies Group sold 14,100 Arbutus Biopharma shares in Q2 2021, an estimated $47K.
  • Jefferies Group first reported a position in Arbutus Biopharma in Q2 2016 and held it in 5 quarters.
  • Jefferies Group's Arbutus Biopharma position peaked at $47K in Q1 2021.
  • 91 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.